These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22380407)

  • 1. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
    Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
    Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
    J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of O⁶ -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India.
    Nehru GA; Pai R; Samuel P; Chacko AG; Chacko G
    Neurol India; 2012; 60(5):481-6. PubMed ID: 23135024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and genomic features of gliosarcomas.
    Lee D; Kang SY; Suh YL; Jeong JY; Lee JI; Nam DH
    J Neurooncol; 2012 May; 107(3):643-50. PubMed ID: 22270848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications.
    Kang SH; Park KJ; Kim CY; Yu MO; Park CK; Park SH; Chung YG
    J Neurooncol; 2011 Feb; 101(3):477-86. PubMed ID: 20556478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ
    Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
    Frandsen J; Orton A; Jensen R; Colman H; Cohen AL; Tward J; Shrieve DC; Suneja G
    J Neurosurg; 2018 Apr; 128(4):1133-1138. PubMed ID: 28621623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
    Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
    J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
    Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
    Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic impact of O6-methylguanine DNA methyltransferase and epidermal growth factor receptor expressions on primary gliosarcoma: a clinicopathologic and immunohistochemical study of seven cases at a single institution.
    Lin JW; Wu YT; Chang IW
    Indian J Pathol Microbiol; 2011; 54(4):683-7. PubMed ID: 22234090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
    Kavouridis VK; Ligon KL; Wen PY; Iorgulescu JB
    J Neurooncol; 2022 May; 158(1):111-116. PubMed ID: 35474499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
    Ellingson BM; Cloughesy TF; Pope WB; Zaw TM; Phillips H; Lalezari S; Nghiemphu PL; Ibrahim H; Naeini KM; Harris RJ; Lai A
    Neuroimage; 2012 Jan; 59(2):908-16. PubMed ID: 22001163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
    Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
    Kakkar A; Kumar A; Jha P; Goyal N; Mallick S; Sharma MC; Suri A; Singh M; Kale SS; Julka PK; Sarkar C; Suri V
    Neuropathology; 2014 Aug; 34(4):333-42. PubMed ID: 24521400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
    Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
    Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience.
    Schlosser S; Wagner S; Mühlisch J; Hasselblatt M; Gerss J; Wolff JE; Frühwald MC
    Pediatr Blood Cancer; 2010 Feb; 54(2):228-37. PubMed ID: 19856394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
    Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
    Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between response to primary treatments and MGMT status in glioblastoma.
    Franceschi E; Tosoni A; Pozzati E; Brandes AA
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
    Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.